Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 10,705 | 10,775 | 13,278 | 5,382 | 5,390 |
| TOTAL | $11,493 | $11,294 | $13,436 | $5,736 | $5,864 |
| Non-Current Assets | |||||
| PPE Net | 12 | 7 | 4 | 2 | 1 |
| TOTAL | $12 | $7 | $4 | $2 | $1 |
| Total Assets | $11,505 | $11,301 | $13,440 | $5,738 | $5,865 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 516 | 235 | 427 | 253 | 184 |
| Accrued Expenses | 1,150 | 971 | 843 | 762 | 735 |
| TOTAL | $1,666 | $1,206 | $1,270 | $1,015 | $919 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,666 | $1,206 | $1,270 | $1,015 | $919 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 10,764 | 5,727 | 4,798 | 4,778 | 1,055 |
| Common Shares | 1 | N/A | N/A | N/A | N/A |
| Retained earnings | -152,683 | -150,291 | -148,125 | -146,356 | -144,730 |
| TOTAL | $9,839 | $10,095 | $12,170 | $4,723 | $4,946 |
| Total Liabilities And Equity | $11,505 | $11,301 | $13,440 | $5,738 | $5,865 |